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Summary
Background Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic 
colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after 
chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of 
combining first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastatic 
colorectal cancer with liver metastases. The studies were designed for combined analysis of overall survival.
Methods FOXFIRE, SIRFLOX, and FOXFIRE-Global were randomised, phase 3 trials done in hospitals and specialist 
liver centres in 14 countries worldwide (Australia, Belgium, France, Germany, Israel, Italy, New Zealand, Portugal, 
South Korea, Singapore, Spain, Taiwan, the UK, and the USA). Chemotherapy-naive patients with metastatic 
colorectal cancer (WHO performance status 0 or 1) with liver metastases not suitable for curative resection or ablation 
were randomly assigned (1:1) to either oxaliplatin-based chemotherapy (FOLFOX: leucovorin, fluorouracil, and 
oxaliplatin) or FOLFOX plus single treatment SIRT concurrent with cycle 1 or 2 of chemotherapy. In FOXFIRE, 
FOLFOX chemotherapy was OxMdG (oxaliplatin modified de Gramont chemotherapy; 85 mg/m² oxaliplatin infusion 
over 2 h, L-leucovorin 175 mg or D,L-leucovorin 350 mg infusion over 2 h, and 400 mg/m² bolus fluorouracil followed 
by a 2400 mg/m² continuous fluorouracil infusion over 46 h). In SIRFLOX and FOXFIRE-Global, FOLFOX 
chemotherapy was modified FOLFOX6 (85 mg/m² oxaliplatin infusion over 2 h, 200 mg leucovorin, and 
400 mg/m² bolus fluorouracil followed by a 2400 mg/m² continuous fluorouracil infusion over 46 h). Randomisation 
was done by central minimisation with four factors: presence of extrahepatic metastases, tumour involvement of the 
liver, planned use of a biological agent, and investigational centre. Participants and investigators were not masked to 
treatment. The primary endpoint was overall survival, analysed in the intention-to-treat population, using a two-stage 
meta-analysis of pooled individual patient data. All three trials have completed 2 years of follow-up. FOXFIRE is 
registered with the ISRCTN registry, number ISRCTN83867919. SIRFLOX and FOXFIRE-Global are registered with 
ClinicalTrials.gov, numbers NCT00724503 (SIRFLOX) and NCT01721954 (FOXFIRE-Global).
Findings Between Oct 11, 2006, and Dec 23, 2014, 549 patients were randomly assigned to FOLFOX alone and 
554 patients were assigned FOLFOX plus SIRT. Median follow-up was 43∙3 months (IQR 31∙6–58∙4). There were 
411 (75%) deaths in 549 patients in the FOLFOX alone group and 433 (78%) deaths in 554 patients in the FOLFOX 
plus SIRT group. There was no difference in overall survival (hazard ratio [HR] 1∙04, 95% CI 0∙90–1∙19; p=0·61). The 
median survival time in the FOLFOX plus SIRT group was 22∙6 months (95% CI 21∙0–24∙5) compared with 
23∙3 months (21∙8–24∙7) in the FOLFOX alone group. In the safety population containing patients who received at 
least one dose of study treatment, as treated, the most common grade 3–4 adverse event was neutropenia (137 [24%] 
of 571 patients receiving FOLFOX alone vs 186 (37%) of 507 patients receiving FOLFOX plus SIRT). Serious adverse 
events of any grade occurred in 244 (43%) of 571 patients receiving FOLFOX alone and 274 (54%) of 507 patients 
receiving FOLFOX plus SIRT. 10 patients in the FOLFOX plus SIRT group and 11 patients in the FOLFOX alone 
group died due to an adverse event; eight treatment-related deaths occurred in the FOLFOX plus SIRT group and 
three treatment-related deaths occurred in the FOLFOX alone group.
Interpretation Addition of SIRT to first-line FOLFOX chemotherapy for patients with liver-only and liver-dominant 
metastatic colorectal cancer did not improve overall survival compared with that for FOLFOX alone. Therefore, early 
use of SIRT in combination with chemotherapy in unselected patients with metastatic colorectal cancer cannot be 
recommended. To further define the role of SIRT in metastatic colorectal cancer, careful patient selection and studies 
investigating the role of SIRT as consolidation therapy after chemotherapy are needed.
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Introduction
Metastatic disease affects approximately 40–50% of the 
more than one million patients diagnosed with 
colorectal cancer worldwide each year.1,2 5-year overall 
survival for patients with metastatic colorectal cancer is 
approximately 13%.1 The liver is the dominant site of 
metastases in colorectal cancer and liver metastases are 
the commonest cause of death for patients with 
colorectal cancer.3
Modest, but steady, advances in systemic therapy have 
improved the outlook for patients with metastatic 
colorectal cancer over the past two decades.4 Nevertheless, 
surgery remains the only curative treatment. In this 
disease, compelling evidence suggests that improved 
local control of colorectal liver metastases could translate 
into prolonged overall survival. After complete resection 
of liver metastases from metastatic colorectal cancer, 
approximately 35–40% of patients survive for 5 years.5 
In the European Organisation for Research and 
Treatment of Cancer (EORTC) intergroup CLOCC 400046 
randomised study of the addition of radiofrequency 
ablation with or without surgery to chemotherapy in 
119 patients with up to nine colorectal liver metastases, a 
significant effect on progression-free survival did 
translate into a significant overall survival benefit.
At present, the proportion of patients eligible for 
surgical resection is only 20%.7 Among the liver-directed 
therapies that might improve local control and increase 
downsizing of tumours to operability, selective internal 
radiation therapy (SIRT) is a leading technology.8 
SIR-Spheres Y-90 resin microspheres (Sirtex Medical 
Limited; Sydney, NSW, Australia) containing the β-emitter 
yttrium-90 (Y-90) are delivered into the arterial supply of 
the liver under fluoroscopic guidance. The delivery of the 
resin microspheres into branches of the hepatic artery, 
which supplies the majority of blood to liver tumours, 
results in selective targeting by high-dose radiotherapy 
because the healthy liver is supplied predominantly by 
the portal venous system and therefore relatively spared 
from radiation exposure.9
Research in context
Evidence before this study
Metastatic disease affects up to 50% of the more than 
one million patients diagnosed with colorectal cancer worldwide 
every year. The liver is the dominant site of metastases in 
colorectal cancer; liver metastases are the commonest cause of 
death for patients with colorectal cancer. Amongst the 
liver-directed therapies that might improve local control and 
increase downsizing of tumours to operability, selective internal 
radiotherapy (SIRT) is a new technology. The efficacy of SIRT in 
third-line or subsequent therapy for metastatic colorectal cancer 
has been evaluated and there are data to suggest that SIRT has 
clinical benefit in patients with colorectal liver metastases with 
liver-dominant disease after chemotherapy. We previously 
published a phase 1/2 trial that established the maximum 
tolerated dose of oxaliplatin-fluorouracil (FOLFOX) 
chemotherapy to combine as concomitant radiosensitising 
chemotherapy with SIRT. At the time of planning our studies 
in 2006, we searched PubMed and Web of Science for articles 
published between Jan 1, 1980, and May 31, 2006, with the 
search terms: “colorectal cancer”, “colon cancer”, “rectal cancer”, 
“oxaliplatin chemotherapy”, “5-fluourouracil chemotherapy”, 
“fluoropyrimidine”, “selective internal radiotherapy”, 
“yttrium-90 microsphere”, “radio-embolization”, 
“radio-embolisation”, “trans-arterial radio-embolization”, “liver 
metastasis”, and “hepatic metastasis” Original articles and review 
articles, published in English, were reviewed. No meta-analyses 
of SIRT treatment of liver metastasis were identified at the time 
of protocol writing in 2006.
Added value of this study
The FOXFIRE, SIRFLOX, and FOXFIRE-Global, randomised 
clinical trials were designed to study whether SIRT in 
combination with FOLFOX chemotherapy as first-line therapy 
for metastatic colorectal cancer can improve overall survival 
compared with FOLFOX alone. To our knowledge, the 
combined study represents the largest, randomised analysis 
performed in the field of interventional oncology to address 
the question of whether improved local control of colorectal 
liver metastases impacts on overall survival. Despite higher 
proportions of patients achieving a response and improved 
liver-specific progression-free survival, the addition of SIRT to 
first-line oxaliplatin-fluorouracil chemotherapy for patients 
with liver-only and liver-dominant metastatic colorectal cancer 
did not improve overall survival or progression-free survival. 
Additionally, to our knowledge, this study provides the most 
comprehensive account of the risk of adverse events which can 
occur secondary to SIRT when it is used in combination with 
FOLFOX chemotherapy.
Implications of all the available evidence
Because of the absence of overall survival benefit, early use of SIRT 
in combination with first-line, oxaliplatin-fluorouracil-based 
chemotherapy in unselected patients with metastatic colorectal 
cancer cannot be recommended. Careful patient selection and 
studies investigating the role of SIRT as a post-chemotherapy 
consolidation therapy are required to define the role of SIRT in 
treating metastatic colorectal cancer.
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Building on our phase 1/2 trial, in which we established 
the maximum tolerated dose of oxaliplatin-fluorouracil 
(FOLFOX) chemotherapy to combine as concomitant 
radiosensitising chemotherapy with SIRT,10 the 
FOXFIRE, SIRFLOX, and FOXFIRE-Global clinical trials 
were designed to study SIRT in combination with 
FOLFOX chemotherapy compared with FOLFOX alone 
as first-line therapy for metastatic colorectal cancer.11,12 
Eligibility criteria and trial designs were pre-planned to 
be similar so that the three trials could be prospectively 
combined for analysis of overall survival and secondary 
endpoints. We previously reported that the combination 
of SIRT with FOLFOX in SIRFLOX13 increased liver-
specific progression-free survival compared with 
FOLFOX chemotherapy alone, but there was no effect on 
overall progression-free survival. In this combined study, 
we sought to address the question of whether improved 
local control of colorectal liver metastases impacts on 
overall survival.
Methods
Study design and participants
The FOXFIRE, SIRFLOX, and FOXFIRE-Global 
randomised, phase 3 trials were done in 14 countries 
(Australia, Belgium, France, Germany, Israel, Italy, New 
Zealand, Portugal, South Korea, Singapore, Spain, Taiwan, 
the UK, and the USA): in 28 hospitals and specialist liver 
centres for FOXFIRE, 87 hospitals or centres for SIRFLOX, 
and 69 hospitals or centres for FOXFIRE-Global (appendix 
pp 28–34). Two complementary trials were originally 
planned (FOXFIRE and SIRFLOX), but the FOXFIRE 
study took longer than anticipated to set up and recruit, so 
a third study (FOXFIRE-Global) was added as an 
independent trial. 
Patients had to be eligible for systemic chemotherapy 
as first-line treatment for metastatic colorectal cancer.11–14 
Eligibility criteria were similar between the three trials, 
but not identical. Similarities and differences are 
highlighted in the combined study protocol paper.14 
Inclusion criteria included histologically confirmed 
colorectal cancer with liver-only or liver-dominant 
metastases with or without the primary tumour in situ, 
WHO performance status of 0 or 1, limited extrahepatic 
disease, age of 18 years or older, and life expectancy 
3 months or longer. The full list of inclusion criteria 
have previously been published.11–14 Eligibility was 
confirmed by haematological, renal, and hepatic 
function tests. Exclusion criteria included ascites, 
cirrhosis, or portal hypertension (all established by 
clinical or radiological assessment); thrombosis of the 
main portal vein; and peripheral neuropathy grade 1 or 
worse. Full lists of exclusion criteria have previously 
been published.11–14 
The trials were done according to the principles of 
ISO14155 Good Clinical Practice and the Declaration of 
Helsinki. All participants provided written, informed 
consent. The protocols for FOXFIRE and SIRLOX trials 
and for this combined study have previously been 
published.11,12,14
Randomisation and masking
In all three trials, patients were randomly assigned (1:1) 
to either FOLFOX chemotherapy alone or FOLFOX plus 
SIRT with minimisation, based on the strata metastasis 
site (liver-only vs liver plus extrahepatic metastases), 
extent of tumour involvement of the liver (≤25% vs >25% 
measured objectively on baseline CT scan), planned use 
of a biological agent, and investigational centre.
In FOXFIRE, patients were allocated using minim-
isation with a probability of 0·8 to the treatment that 
most reduced the imbalance of the above factors. If there 
were equal numbers of patients in each treatment group, 
then patients were allocated to each treatment with a 
probability of 0·5. The first 30 treatments were allocated 
using (simple) block randomisation (using variable block 
sizes of 2, 4, and 6 in a ratio of 1:2:1). In SIRFLOX and 
FOXFIRE-Global, an imbalance window of 5 was used; if 
the treatment imbalance between the two groups was 
less than 5, the treatment was randomly allocated. If the 
treat ment imbalance reached 5, the next treatment 
allocation was forced to reduce the imbalance. In 
FOXFIRE, computer-based randomisation was done 
centrally at the Oncology Clinical Trials Office (OCTO; 
Oxford, UK). While the trial was in progress, access to 
the full randomisation lists was restricted to the Database 
Development Manager at OCTO and the trial statistician 
at the Centre for Statistics in Medicine (CSM; Oxford, 
UK). In SIRFLOX and FOXFIRE-Global, randomisation 
was done centrally at the National Health and Medical 
Research Council Clinical Trials Centre (Camperdown, 
NSW, Australia) via an interactive voice response system. 
Participants were enrolled by the investigators in all 
three trials. As none of the trials were masked, once 
patients were allocated to treatment, participants, all 
members of the trial team, and treating medical staff 
knew the treatment allocation.
Procedures
In FOXFIRE, systemic FOLFOX chemotherapy con-
sisted of OxMdG (oxaliplatin modified de Gramont 
chemo therapy; 85 mg/m² oxaliplatin infusion over 2 h, 
L-leucovorin 175 mg or D,L-leucovorin 350 mg infusion 
over 2 h, and 400 mg/m² bolus fluorouracil followed by 
a 2400 mg/m² continuous fluorouracil infusion over 
46 h). Systemic FOLFOX chemotherapy in SIRFLOX 
and FOXFIRE-Global consisted of modified FOLFOX6 
(85 mg/m² oxaliplatin infusion over 2 h, 200 mg 
leucovorin, and 400 mg/m² bolus fluorouracil followed 
by a 2400 mg/m² continuous fluorouracil infusion over 
46 h). Oxaliplatin and fluorouracil were from hospital 
stock; D,L-leucovorin referred to the racemic mixture. 
In FOXFIRE, protocol chemotherapy was 12 cycles; in 
SIRFLOX and FOXFIRE-Global, protocol chemotherapy 
continued until disease progression or dose-limiting 
See Online for appendix
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toxicity. The oxaliplatin dose was reduced from 
85 mg/m² to 60 mg/m² for three cycles from the cycle 
coinciding with SIRT administration and for two cycles 
thereafter, based on phase 1/2 data.10 Dose modifications 
were permitted in line with standard care (appendix 
pp 3–8). Each chemotherapy cycle lasted 14 days. 
We used a hepatic arteriogram and a liver-to-lung 
breakthrough nuclear medicine scan to assess patient 
suitability to receive SIRT. We used the patient’s body 
surface area, percentage of tumour involvement, and 
magnitude of liver-to-lung shunting to establish the 
activity (GBq) per dosing chart.12 Planned SIRT was 
done on cycle 1 day 3 or 4 or cycle 2 day 3 or 4.10 
In FOXFIRE, patients could receive anti-VEGF 
(eg, bevacizumab) or anti-EGFR (eg, cetuximab) from 
cycle 1 in the FOLFOX alone group and from cycle 7 
onwards in the FOLFOX plus SIRT group. In SIRFLOX 
and FOXFIRE-Global, patients could receive 
bevacizumab from cycle 1 in the FOLFOX alone group 
and from cycle 4 onwards in the FOLFOX plus SIRT 
group. The addition of anti-VEGF or anti-EGFR 
treatments to protocol therapy was at the discretion of 
the treating physician and doses prescribed were 
according to local policy at the treating centre.
We assessed patients by CT scan every 8–12 weeks 
until hepatic progression. Follow-up assessments 
included clinical assessment; CT of chest, abdomen, and 
pelvis; and health related quality-of-life (HRQoL) 
assessment.11,12,14 Scans were independently reviewed by 
Pharmtrace (Berlin, Germany) for overall and hepatic 
progression in FOXFIRE using Response Evaluation 
Criteria in Solid Tumors (RECIST; version 1.0) and in 
SIRFLOX with RECIST (version 1.0) with minor 
modifications.13 Independent reviews were not done in 
FOXFIRE-Global. We assessed all patients for suitability 
for liver resection at 6 months. After protocol therapy, 
patients could receive any subsequent treatment as best 
available care determined by the treating physician. All 
patients were followed up until death or for a minimum 
of 2 years.
Health-related quality of life was assessed with the 
EuroQol-5D three-level questionnaire (EQ-5D-3L), a 
generic HRQoL instrument15 measuring health in five 
dimensions (mobility, self-care, usual activities, pain or 
discomfort, and anxiety or depression), which is 
summarised as a utility score.16 The EQ-5D-3L was 
administered during clinic visits at baseline, between the 
second and the third months after randomisation, at 
6 months, at 12 months, and once per year until 
60 months from the start of protocol treatment. Grading 
of adverse events used the National Cancer Institute 
Common Terminology Criteria for Adverse Events 
(version 3).
Outcomes
The primary outcome of this analysis was overall survival, 
defined as the time from randomisation to death from any 
cause, with patients who were still alive censored at their 
last known follow-up date. Secondary outcomes included 
progression-free survival, liver-specific progression-free 
survival, HRQoL, tumour response, liver resection rate, 
and adverse event profiles. The primary and secondary 
outcomes in each of the individual trials are in the appendix 
(p 13). We defined progression-free survival as the time 
from randomisation to radiological progression or death 
from any cause, whichever occurred first. Patients who did 
not progress or die during the trial were censored at their 
last known progression-free follow-up date. Liver-specific 
progression-free survival was defined as the time from 
randomisation to radiological hepatic progression. 
Progression not involving the liver and death before 
progression were regarded as competing events. 
We deemed hepatic progression to have occurred 
immediately before non-liver progression in patients who 
had identical hepatic and extrahepatic progression dates. 
Patients who withdrew from study treatment before 
documented progression were censored at commencement 
of non-study treatment for both the progression-free 
survival and liver-specific progression-free survival 
endpoints. Time of resection was not deemed a censoring 
point for progression-free survival or liver-specific 
progression-free survival. The proportion of patients 
achieving an objective response in each treatment group 
was defined as the number of patients achieving a complete 
or partial response at any point during the trial, up to their 
first occurrence of hepatic resection, over the number 
randomised in that group (early deaths by any cause and 
unknown responses were included in the demominator). 
The percentage resected in each group was defined as the 
number of patients who underwent a hepatic resection 
divided by the number randomly assigned to that group.
Statistical analysis
For the primary combined overall survival analysis, a 
sample size of 810 was originally calculated, but 
subsequently updated to 1075 patients (710 deaths) using a 
protocol-specified hazard ratio (HR) of 0∙8, with a control 
group median overall survival of 19∙7 months and SIRT 
group median overall survival of 24·6 months, two-sided 
5% significance, 80% power, and allowing for 5% non-
compliance.14 The updated sample size allowed for a 
higher median overall survival, the addition of biological 
agents to protocol chemotherapy (planned use added as a 
stratification factor to the randomisation in May, 2011, for 
FOXFIRE and SIRFLOX, and incorporated in FOXFIRE-
Global since set-up) and crossover in both directions. The 
study also had 80% power to detect a 6-month overall 
survival benefit in the subgroup of patients with metastatic 
disease restricted to the liver: 708 patients (463 deaths) 
were needed. The cutoff for analysis was chosen such that 
there was a minimum of 710 deaths overall and 463 deaths 
in the liver-only subgroup (assuming a 6-month increase 
in overall survival in the SIRT-treated, liver-metastasis-
only patients) and a minimum follow-up of 2 years since 
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the last patient was randomly assigned to treatment. 
We did two interim toxicity and safety analyses with the 
combined data from the FOXFIRE and SIRFLOX trials 
8 months after at least 80 patients were randomly assigned 
(40 patients per trial) and 8 months after 300 were 
randomly assigned (minimum of 120 patients per trial); 
FOXFIRE-Global was not included in the interim analyses 
on the combined data.
We calculated median follow-up time using the reverse 
Kaplan-Meier method. We did all efficacy analyses on an 
intention-to-treat basis per the published statistical analysis 
plan.14 We estimated overall survival and progression-free 
survival for each trial using Kaplan-Meier survival curves, 
unadjusted log-rank tests, and Cox proportional hazards 
survival models. We checked the proportionality 
assumption using Schoenfeld residuals. HRs for overall 
survival and progression-free survival from the individual 
trials were combined using a two-stage, fixed-effect, 
inverse-variance weighted individual participant data 
meta-analysis approach.17 The I² statistic indicates the 
proportion of variation in the treatment effect that is due to 
heterogeneity rather than chance. Sensitivity analyses 
included using only eligible patients, and using radiological 
scan data as reported by sites for all three trials. We 
assessed liver-specific progression-free survival using 
cumulative incidence curves, and Fine and Gray 
subdistribution hazard regression models18 stratified by 
trial. We checked model assumptions by including a time-
varying coefficient for treatment. We also estimated cause-
specific hazards.19 For overall survival, progression-free 
survival, and liver-specific progression-free survival, we 
investigated the potential treatment benefit in patients 
presenting with disease confined to the liver using survival 
models stratified by trial (prespecified subgroup analysis). 
The odds of patients having a resection or achieving a 
response (overall and liver-specific) were compared 
between treatment groups by pooling individual trial odds 
ratios (OR) using two-stage individual participant data 
meta-analysis. The EQ-5D-3L health states reported by 
patients were expressed as utility scores derived by 
weighting the responses using US EQ-5D valuations16 with 
a score of 1 corresponding to full health and 0 to death. 
A minimum clinically significant difference in EQ-5D 
scores of 0·08 has been suggested across all cancers.20 We 
used analysis of covariance to analyse differences in 
EQ-5D-3L utility scores between the two treatment groups, 
adjusted for EQ-5D-3L baseline values. We made post-hoc 
comparisons between treatment groups of treatment 
received after protocol therapy using the Mantel-Haenszel 
test, stratifying by trial.
We did safety analyses on patients who received at least 
one dose of chemotherapy in either group and on an as-
treated basis. We included adverse events reported up to 
28 days after the end of trial treatment or 7 months after 
Figure 1: Trial profile
OxMdG and mFOLFOX6 are equivalent oxaliplatin-fluorouracil-based FOLFOX chemotherapy regimens. FOLFOX=leucovorin, fluorouracil, and oxaliplatin. MDT=multidisciplinary team. 
mFOLFOX6=modified FOLFOX. OxMdG=oxaliplatin modified de Gramont chemotherapy. SIRT=selective internal radiotherapy. *Includes 122 ineligible patients; 49 protocol waivers and 
73 retrospectively identified. †Discontinuation data were available for patients in FOXFIRE and for a subset of patients in SIRFLOX, but were not available for patients in FOXFIRE-Global.
FOXFIRE
1282 discussed at MDT
           meeting or screened
364 randomly assigned
182 assigned OxMdG 182 assigned OxMdG 
 plus SIRT
179 started FOLFOX 
 chemotherapy
180 started FOLFOX 
 chemotherapy
167 SIRT given
SIRFLOX
561 screened
530 randomly assigned
263 assigned mFOLFOX6
252 started FOLFOX 
 chemotherapy
267 assigned mFOLFOX6 
 plus SIRT
263 started FOLFOX 
 chemotherapy
247 SIRT given
FOXFIRE-Global
240 screened
209 randomly assigned
104 assigned mFOLFOX6 105 assigned mFOLFOX6 
 plus SIRT
102 started FOLFOX 
 chemotherapy
102 started FOLFOX 
 chemotherapy
 93 SIRT given
918 excluded
 712 did not meet 
  inclusion or  
  exclusion criteria
 110 patient refusal
 96 other reason
31 failed screening 31 failed screening
1103 included in individual participant data analysis*†
549 FOLFOX chemotherapy group
554 FOLFOX chemotherapy plus SIRT group
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randomisation, whichever was earlier (deemed the safety 
window). We combined individual trial ORs using 
two-stage individual participant data meta-analysis to 
assess the association of grade 3 or worse adverse 
events with treatment. An independent data and safety 
monitoring committee oversaw the study. Formal interim 
monitoring of the accumulating data was done at 
regular intervals (approximately every 6 months) by the 
independent data and safety monitoring committee for 
each trial separately.
Data were analysed with Stata (version 14.1) and R 
(version 3.3.2). All hypothesis tests were two-sided. We used 
a significance level of 5%. Partial dates were imputed, but 
no statistical imputation techniques were used.
FOXFIRE is registered with the ISRCTN registry, 
number ISRCTN83867919. SIRFLOX and FOXFIRE-
Global are registered with ClinicalTrials.gov, numbers 
NCT00724503 (SIRFLOX) and NCT01721954 
(FOXFIRE-Global).
Role of the funding source
The sponsor had no role in the FOXFIRE study design, 
data collection, or data analysis. Employees of Sirtex 
were involved in all stages of the SIRFLOX and 
FOXFIRE-Global studies, and in the process of 
combining the three trial datasets. The funders had no 
role in data analysis or interpretation for the combined 
study. The sponsor reviewed the manuscript and 
provided comments. JMo, PD, PSV, and SL had full 
access to all of the data in the study and the corresponding 
author had final responsibility for the decision to submit 
for publication.
Results
Between Oct 11, 2006, and Dec 23, 2014, 1103 patients 
were enrolled and randomly assigned to either FOLFOX 
chemotherapy (n=549) or FOLFOX plus single treatment 
SIRT (n=554) (figure 1). Patients were recruited for the 
FOXFIRE study between Nov 13, 2009, and Oct 31, 2014. 
Patients in the SIRFLOX study were recruited between 
FOLFOX alone 
(n=549)
FOLFOX plus SIRT 
(n=554)
Age at randomisation (years) 62·7 (23·1–89·0) 63·4 (28·4–89·6)
Time since diagnosis of 
primary tumour to 
randomisation (months)
1·4 (0·9–2·3) 1·4 (0·9–2·3)
Time since diagnosis of liver 
metastases to randomisation 
(months)
1·2 (0·8–1·8) 1·2 (0·7–1·8)
Sex
Male 361 (66%) 363 (66%)
Female 187 (34%) 191 (34%)
Missing 1 (<1%) 0
WHO performance status
0 347 (63%) 354 (64%)
1 200 (36%) 198 (36%)
Missing 2 (<1%) 2 (<1%)
Primary tumour site
Colon 392 (71%) 421 (76%)
Rectum 137 (25%) 116 (21%)
Not categorisable* 8 (1%) 5 (1%)
Missing 12 (2%) 12 (2%)
Primary tumour in situ
Yes 302 (55%) 278 (50%)
No 246 (45%) 275 (50%)
Missing 1 (<1%) 1 (<1%)
Previous adjuvant chemotherapy
Yes 28 (5%) 31 (6%)
No 520 (95%) 523 (94%)
Missing 1 (<1%) 0
Metastases present at initial diagnosis
Yes (synchronous) 475 (87%) 483 (87%)
No (metachronous) 71 (13%) 68 (12%)
Missing 3 (1%) 3 (1%)
(Table 1 continues in next column)
FOLFOX alone 
(n=549)
FOLFOX plus SIRT 
(n=554)
(Continued from previous column)
Extrahepatic metastases status†‡
No 358 (65%) 355 (64%)
Yes 191 (35%) 199 (36%)
Extent of liver involvement†
≤25% 380 (69%) 374 (68%)
>25% 168 (31%) 179 (32%)
Missing 1 (<1%) 1 (<1%)
Intention to treat with biological agents†
Yes 299 (54%) 298 (54%)
No 153 (28%) 153 (28%)
Not applicable§ 97 (18%) 103 (19%)
Data are median (range) for age, median (IQR) for times since diagnosis, or n (%). 
SIRT=selective internal radiotherapy. *Site of primary tumour recorded as both 
colon and rectum; the only options in FOXFIRE were colon or rectum. 
†Minimisation factors; treating site was also a minimisation factor. ‡Extrahepatic 
disease permitted as per trial protocols were FOXFIRE: no more than five 
metastases in the lung and metastases should have been, in the opinion of either 
the local multidisciplinary team meeting or after central review of scans arranged 
via the trials office, amenable to future definitive local therapy, in addition to lung 
metastases, a single site of other extrahepatic disease was permitted (eg, multiple 
lymph nodes in one lymph node region) after approval by the trials office; for 
SIRFLOX and FOXFIRE-Global: limited extrahepatic metastases in the lung, lymph 
nodes, or both were permitted, no more than five nodules in the metastases in 
the lung were allowed, which were no more than 1 cm in diameter or up to 1·7 cm 
in diameter per single lesion; involvement of lymph nodes in one single anatomic 
area (pelvis, abdomen, or chest) was permitted provided their longest diameter 
measured less than 2 cm. §Intention to treat with a biological agent was not a 
minimisation factor for these patients because it was introduced after these 
patients entered the study.
Table 1: Baseline characteristics of participants in the combined study
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Oct 11, 2006, and April 25, 2013. Patients were recruited 
for the FOXFIRE-Global study between May 20, 2013, and 
Dec 23, 2014. End of follow-up was Oct 31, 2016, for 
FOXFIRE, June 1, 2016, for SIRFLOX, and Nov 30, 2016, 
for FOXFIRE-Global, ensuring 2 years of follow-up after 
the last patient was enrolled (appendix p 13). The data 
lock dates for analysis were Dec 23, 2016, for SIRFLOX 
and FOXFIRE-Global and Feb 6, 2017, for FOXFIRE. 
Minimisation factors and other baseline characteristics 
were evenly balanced between treatment groups and 
between trials (table 1, appendix pp 14–15). Median follow-
up was 43∙3 months (IQR 31∙6–58∙4).
In the first 12 cycles of treatment, 3193 (59% of 5369) 
oxaliplatin cycles in the FOLFOX plus SIRT group and 
3608 (68%) of 5344 cycles in the FOLFOX alone group 
were at full protocol dose. Dose reduction data were not 
readily available. The median number of cycles of 
FOLFOX treatment was 12 (IQR 7–13) in the FOLFOX 
plus SIRT group and 12 (7–15) in the FOLFOX alone 
group. Bevacizumab was given to 197 (36%) of 
554 patients in the FOLFOX plus SIRT group and 
256 (47%) of 549 patients in the FOLFOX alone group. 
In FOXFIRE, 13 (4%) of 364 patients received cetuximab 
(four in the FOLFOX plus SIRT group and nine in the 
FOLFOX group). After finishing protocol therapy, fewer 
patients in the FOLXFOX plus SIRT group were given 
irinotecan, fluoropyrimidine, anti-VEGF, or anti-EGFR 
systemic therapies upon progression than were patients 
in the FOLFOX alone group (appendix p 16). 66 (12%) of 
549 patients randomly assigned to the FOLFOX alone 
group received SIRT in a later course of therapy, whereas 
47 (8%) of 554 patients randomly assigned to SIRT did 
not receive SIRT.
There were 844 (77%) deaths in 1103 patients in the 
intention-to-treat population over the follow-up period: 
296 (81%) deaths in 364 patients in FOXFIRE, 424 (80%) 
in 530 patients in SIRFLOX, and 124 (59%) in 209 patients 
in FOXFIRE-Global. There were 433 (78%) deaths in 
554 patients in the FOLFOX plus SIRT group and 
411 (75%) in 549 patients in the FOLFOX alone group. 
The median survival time in the FOLFOX plus SIRT 
group was 22∙6 months (95% CI 21∙0–24∙5) compared 
with 23∙3 months (21∙8–24∙7) in the FOLFOX alone 
group; the pooled HR was 1∙04 (95% CI 0∙90–1∙19, 
p=0∙61; figure 2A, C). Overall survival in each trial is 
shown in the appendix (p 9). No difference between 
treatment groups was found in the prespecified, liver-
metastasis-only subgroup analysis of overall survival 
Figure 2: Overall survival (A, C) and progression-free survival (B, D) in the intention-to-treat population
HR=hazard ratio. SIRT=selective internal radiotherapy. Red line indicates the overall, pooled estimate. Size of shaded grey boxes indicates the relative weight of 
the study.
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(261 [73%] of 358 patients in the FOLFOX group, median 
overall survival 24·6 months, 95% CI 22·1–26·4; 
264 [74%] of 355 patients in the FOLFOX plus SIRT 
group, 24·5 months, 22·3–26·3; pooled HR 1∙00, 95% CI 
0∙85–1∙19, p=0∙96). In a sensitivity analysis of overall 
survival excluding ineligible patients (62 [11%] of 
549 patients in the FOLFOX group and 60 [11%] of 
554 patients in the FOLFOX plus SIRT group were 
ineligible; reasons for ineligibility not reported), there 
were 360 deaths (74%) in 487 patients in the FOLFOX 
group and 382 deaths (77%) in 494 patients in the 
FOLFOX plus SIRT group. Median overall survival was 
23·9 months (95% CI 21·8–25·0) in the FOLFOX group 
and 23·4 months (21·8–25·2) in the FOLFOX plus SIRT 
group; pooled HR was 1·01 (95% CI 0·88–1·17, p=0·86). 
Subgroup comparisons for overall survival of the 
prespecified subgroups metastatic site, liver involvement, 
age, sex, WHO performance status, and tumour in situ, 
and the post-hoc subgroups primary tumour site, 
bevacizumab administration, and timing of metastasis 
are shown in figure 3.
941 (85%) of 1103 patients had an observed radiological 
progression or died before progression: 304 (84%) of 
364 patients in FOXFIRE, 452 (85%) of 530 patients in 
SIRFLOX, and 185 (89%) of 209 patients in FOXFIRE-
Global. 467 (85%) of 549 patients in the FOLFOX group 
and 474 (86%) of 554 patients in the FOLFOX plus SIRT 
had progression or died. Progression-free survival was not 
significantly different between treatment groups (pooled 
HR 0∙90, 95% CI 0∙79–1∙02, p=0∙11; figure 2B, D). The 
median progression-free survival in the FOLFOX plus 
SIRT group was 11∙0 months (95% CI 10∙2–11∙8) 
compared with 10∙3 months (9∙7–10∙9) in the FOLFOX 
alone group. Similar results were found in the pre specified 
subgroup analysis restricted to patients with liver-only 
metastatic colorectal cancer at baseline; 297 (83%) of 
358 patients in the FOLFOX group had progressed or died 
in the liver-only subgroup analysis (median progression-
free survival 11·1 months, 95% CI 10·0–12·1); 292 (82%) of 
355 patients in the FOLFOX plus SIRT group had 
progressed or died (11·9 months, 11·0–13·8; HR 0∙86, 
95% CI 0∙73–1∙01, p=0∙066). The results of a prespecified 
sensitivity analysis using radiological scan data as reported 
by sites from all three trials were consistent with the 
analysis of the centrally reviewed data (HR 0∙91, 95% CI 
0∙80–1∙03, p=0∙15).
In 271 (49%) of 549 patients in the FOLFOX and 
173 (31%) of 554 patients in the FOLFOX plus SIRT group, 
first progression events were radiologically observed in 
the liver (figure 4A). The cumulative incidence of first 
progression in the liver was lower in the FOLFOX plus 
SIRT group than the FOLFOX alone group (figure 4A; 
appendix p 17). The cumulative incidence of progression 
within the liver in the first 12 months of follow-up was 22% 
(95% CI 19–26) in the FOLFOX plus SIRT group and 39% 
(35–43) in the FOLFOX alone group. In 196 (36%) of 
549 patients in the FOLFOX group and 301 (54%) of 
554 patients in the FOLFOX plus SIRT group, first 
progression was extrahepatic or death occurred before 
recorded radiological progression (figure 4B, appendix 
p 17). The cumulative incidence of first progression 
occurring outside the liver or death before recorded 
radiological progression was higher in the FOLFOX plus 
Figure 3: Treatment effect on overall survival by subgroup
HR=hazard ratio. SIRT=selective internal radiotherapy.
Figure 4: Cumulative incidence of radiological progression within the liver (A) and non-liver progression or 
death without radiological progression having been documented (B)
HR=hazard ratio. SIRT=selective internal radiotherapy.
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SIRT group than in the FOLFOX alone group (figure 4B; 
appendix p 17). The cumulative incidence of progression 
outside the liver or death before recorded radiological 
progression in 12 months of follow-up was 33% (95% CI 
29–37) in the FOLFOX plus SIRT group and 19% (16–23) 
in the FOLFOX alone group. Cause-specific HRs were in 
the same direction as, and of similar magnitudes to, the 
subdistribution HRs (appendix p 17).
An objective (complete or partial) response over the 
study duration was achieved in 746 (68%) of 1103 patients; 
400 (72%) of 554 in the FOLFOX plus SIRT group and 
346 (63%) of 549 in the FOLFOX alone group (pooled 
OR 1∙52, 95% CI 1∙18–1∙96, p=0∙0012; appendix pp 10, 
17). An objective response was observed in more patients 
in the FOLFOX plus SIRT group than in the FOLFOX 
alone group in each of the individual trials (appendix 
p 17). The odds of achieving an objective response in the 
liver were also higher in the FOLFOX plus SIRT group 
than in the FOLFOX alone group (pooled OR 1∙78, 
95% CI 1∙37–2∙31, p<0∙0001; appendix p 18).
FOLFOX alone (n=571) FOLFOX plus SIRT (n=507)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Overall 189 (33%) 266 (47%) 103 (18%) 11 (2%) 131 (26%) 239 (47%) 126 (25%) 10 (2%)
Haematological 102 (18%) 108 (19%) 56 (10%) 1 (<1%) 109 (21%) 144 (28%) 86 (17%) 1 (<1%)
Neutropenia 50 (9%) 89 (16%) 48 (8%) 1 (<1%) 55 (11%) 115 (23%) 71 (14%) 0
Febrile neutropenia 0 11 (2%) 5 (1%) 0 0 25 (5%) 7 (1%) 1 (<1%)
Thrombocytopenia 77 (13%) 6 (1%) 1 (<1%) 0 153 (30%) 37 (7%) 2 (<1%) 0
Leucopenia 28 (5%) 10 (2%) 3 (1%) 0 41 (8%) 20 (4%) 10 (2%) 0
Non-haematological 265 (46%) 232 (41%) 61 (11%) 10 (2%) 219 (43%) 218 (43%) 59 (12%) 9 (2%)
Fatigue 275 (48%) 28 (5%) 0 0 261 (51%) 43 (8%) 0 0
Diarrhoea 256 (45%) 35 (6%) 2 (<1%) 0 189 (37%) 33 (7%) 1 (<1%) 0
Pulmonary embolism 1 (<1%) 7 (1%) 19 (3%) 0 2 (<1%) 4 (1%) 24 (5%) 0
Neuropathy peripheral 307 (54%) 32 (6%) 1 (<1%) 0 273 (54%) 18 (4%) 0 0
Abdominal pain 95 (17%) 13 (2%) 0 0 151 (30%) 30 (6%) 1 (<1%) 0
SIRT-associated 13 (2%) 9 (2%) 1 (<1%) 0 52 (10%) 24 (5%) 3 (1%) 3 (1%)
Ascites 2 (<1%) 4 (1%) 0 0 23 (5%) 6 (1%) 0 0
Blood bilirubin increased 3 (1%) 2 (<1%) 0 0 6 (1%) 3 (1%) 0 0
Gastric ulcer 0 0 0 0 8 (2%) 3 (1%) 1 (<1%) 0
Hyperbilirubinaemia 1 (<1%) 1 (<1%) 0 0 2 (<1%) 3 (1%) 0 0
Gastrointestinal haemorrhage 0 0 1 (<1%) 0 2 (<1%) 1 (<1%) 2 (<1%) 0
Radiation hepatitis 0 0 0 0 2 (<1%) 2 (<1%) 0 2 (<1%)
Duodenal ulcer 1 (<1%) 0 0 0 4 (1%) 3 (1%) 0 0
Pancreatitis 0 0 0 0 1 (<1%) 2 (<1%) 0 0
Hepatic failure 0 0 0 0 0 1 (<1%) 0 1 (<1%)
Jaundice 0 2 (<1%) 0 0 0 0 0 0
Jaundice cholestatic 0 0 0 0 0 2 (<1%) 0 0
Hepatic encephalopathy 0 0 0 0 0 2 (<1%) 0 0
Duodenitis 0 0 0 0 4 (1%) 1 (<1%) 0 0
Portal hypertension 1 (<1%) 0 0 0 0 1 (<1%) 0 0
Duodenal ulcer haemorrhage 0 0 1 (<1%) 0 0 0 0 0
Cholecystitis acute 0 0 0 0 0 1 (<1%) 0 0
Perihepatic abscess 0 0 0 0 0 1 (<1%) 0 0
Gastritis 4 (1%) 0 0 0 18 (4%) 0 0 0
Oesophagitis 3 (1%) 0 0 0 2 (<1%) 0 0 0
Splenomegaly 1 (<1%) 0 0 0 2 (<1%) 0 0 0
Oesophageal ulcer 0 0 0 0 1 (<1%) 0 0 0
Data are n (%). Table shows grade 3 or worse haematological events occurring in at least 5% of patients, grade 3 or worse non-haematological events occurring in at least 5% 
of patients, and all SIRT-associated adverse events. Worst grade reported per patient per category, sorted by prevalence of grade 3 or worse. SIRT=selective internal 
radiotherapy.
Table 2: Adverse events reported in each treatment group
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Over the follow-up period, 182 (17%) of 1103 patients 
had at least one hepatic resection. Overall, 94 (17%) of 
554 patients in the FOLFOX plus SIRT group and 
88 (16%) of 549 patients in the FOLFOX alone group had 
a resection. The odds of undergoing a resection were not 
significantly different between treatment groups (pooled 
OR 1∙07, 95% CI 0∙78–1∙48, p=0∙67; appendix p 11).
The proportion of patients who had a grade 3 or worse 
adverse event at each treatment cycle by treatment 
group, overall and for haematological adverse events, 
non-haematological adverse events, and neutropenia 
are shown in the appendix (p 12). Of 1078 patients who 
received at least one dose of study treatment in the as-
treated population, 755 (70%) had a grade 3 or worse 
adverse event (up to 28 days after the end of protocol 
chemotherapy or in the first 7 months after 
randomisation, whichever was earlier); 375 (74%) of 
507 patients in the FOLFOX plus SIRT group and 
380 (67%) of 571 patients in the FOLFOX alone group 
(table 2). The odds of a patient having a grade 3 or 
worse adverse event were higher in the FOLFOX plus 
SIRT group than in the FOLFOX alone group (pooled 
OR 1∙42, 95% CI 1∙09–1∙85, p=0∙0089, appendix p 13). 
Of 507 patients who received SIRT, 231 (46%) had a 
haematological grade 3 or worse adverse event, whereas 
165 (29%) of the 571 patients who did not have SIRT 
had a haematological grade 3 or worse adverse event, 
the most frequent being neutropenia (186 [37%] in the 
FOLFOX plus SIRT group vs 138 [24%] in the FOLFOX 
alone group; table 2). Adverse events of grade 1 or 2 
occurring in 10% of patients or more and all grade 3 or 
worse events are shown in the appendix (pp 18–26). 
In FOXFIRE, 15 (8%) of 182 patients in the FOLFOX 
group and 25 (14%) of 182 patients in the FOLFOX plus 
SIRT group discontinued treatment because of an 
adverse event or serious adverse event; data were not 
fully available for SIRFLOX and not available for 
FOXFIRE-Global. Serious adverse events of any grade 
occurred in 244 (43%) of 571 patients receiving FOLFOX 
alone and 274 (54%) of 507 patients receiving FOLFOX 
plus SIRT (appendix p 27). 10 patients in the FOLFOX 
plus SIRT group and 11 patients in the FOLFOX alone 
group died due to an adverse event during the main 
safety window (appendix p 26). 11 (1%) of 844 deaths 
were treatment-related (appendix p 27); eight in 
FOLFOX plus SIRT group and three in the FOLFOX 
alone group. Of the eight treatment-related deaths in 
the FOLFOX plus SIRT group, three deaths due to 
radiation-induced liver disease, two due to 
complications of surgery, one due to liver failure, one 
due to drug-induced pneumonitis, and one due to off-
target delivery of microspheres. There were three 
treatment-related deaths in the FOLFOX alone group: 
one due to complications of surgery, one due to 
neutropenic sepsis, and one due to bowel perforation. 
With specific reference to risk of long-term toxicity to 
the liver from protocol treatment, during continued 
observation after the main safety window until the end 
of the follow-up period, there were two deaths due to 
hepatic events (hepatic failure or ascites) in the 
FOLFOX plus SIRT group.
EQ-5D-3L results were reported for the first 24 months 
of the trial using US EQ-5D valuations; questionnaire 
mean utility value at each timepoint is shown in the 
appendix (p 27). Average unadjusted EQ-5D-3L utility 
scores were not significantly different between treatment 
groups at any time point except at 2–3 months (appendix 
p 27); however, this difference would not be deemed 
clinically meaningful.
Discussion
The FOXFIRE, SIRFLOX, and FOXFIRE-Global 
randomised studies designed to definitively assess the 
combination of SIRT with FOLFOX versus FOLFOX 
alone for colorectal liver metastases in the first-line 
setting have not shown a benefit of adding SIRT on 
overall survival. The combined analysis of these three 
randomised clinical trials shows that a global, 
multidisciplinary trial involving a complex liver-directed 
therapy can be done with adequate power to answer an 
important clinical question.
The efficacy of SIRT in third-line or subsequent therapy 
for metastatic colorectal cancer (ie, salvage therapy of 
chemotherapy-refractory disease) has previously been 
evaluated.21 A randomised trial22 of salvage in patients 
with metastatic colorectal cancer with liver-confined 
disease showed a significant benefit of chemotherapy 
plus SIRT versus chemotherapy alone in time to 
progression. These data suggest that SIRT has clinical 
benefit in patients with colorectal liver metastases with 
liver-dominant disease after chemotherapy.
Metastatic colorectal cancer in which the liver is the 
only site of disease occurs frequently in a subset of 
patients; some of these patients can be resected with 
long-term cures.23 In our study, the significant 
improvement in liver disease control assessed by 
competing risk analyses did not translate to a benefit in 
overall survival. This finding contrasts with that from the 
EORTC CLOCC study,6 which showed that a significant 
effect of radiofrequency ablation with or without surgery 
on progression-free survival translated into a highly 
significant overall survival benefit in patients who did not 
have primary tumour in situ or extrahepatic metastases 
at trial entry. The absence of benefit of the addition of 
SIRT to FOLFOX on progression-free survival and overall 
survival in our combined study could be partly explained 
by the high proportion of patients who developed first 
progression at an extrahepatic site, independently of 
whether the metastases were liver-only at baseline or 
whether there were extrahepatic metastases or primary 
tumour in situ at baseline. Despite the better liver control 
in the FOLFOX plus SIRT group compared with the 
FOLFOX alone group, this observation of extrahepatic 
progression might also explain the absence of a 
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significant difference between the groups in the 
frequency of surgical resection of the liver metastases 
being done during or after protocol therapy. To avoid 
possible ascertainment bias in interpreting responses 
and difficulties differentiating disease progression from 
radiation reaction of the hepatic parenchyma in patients 
undergoing the interventional radiotherapy liver 
procedure, scans were centrally reviewed by independent 
readers. The absence of an overall survival benefit 
suggests that early use of SIRT in combination with first-
line oxaliplatin-based chemotherapy cannot be 
recommended in unselected patients with metastatic 
colorectal cancer.
In our study, the SIRT-treated patients had a similar 
quality of life to the patients who had chemotherapy only. 
Toxicity was higher in the SIRT group, particularly 
neutropenia and SIRT-related expected toxicities. In the 
as-treated population in the FOLFOX plus SIRT group 
(n=507 patients), hepatic failure resulted in death of one 
patient during the main safety window and death of a 
further two patients during extended follow-up. The 
increased toxicity in the SIRT-treated patients did not 
translate into inferior overall survival. This study provides 
the most comprehensive account of the risk of adverse 
events that might occur secondary to SIRT when used in 
combination with FOLFOX chemotherapy.
One possible limitation of our study is that significant 
changes to the management of metastatic colorectal 
cancer occurred during the 8-year recruitment period 
with the introduction of bevacizumab and EGFR 
inhibitors as first-line standards of care, and increased 
use of liver interventions such as surgery and ablation. 
However, there is no reason to believe that treatment 
differences occurred between treatment groups. Another 
limitation is that some patients were found not to have 
met the entry criteria after randomisation. Sensitivity 
analyses excluding all ineligible patients indicated that 
the findings were robust. The non-identical design of the 
individual trials might also be considered a limitation, 
but is accounted for by the use of appropriate statistical 
methods.
Little progress has been reported in improving overall 
survival in molecularly unselected populations since the 
CRYSTAL, PRIME, and TRIBE studies.24–27 In our study, 
crossover was anticipated and 12% of patients 
randomised to FOLFOX alone received SIRT with a later 
line of therapy. Furthermore, 8% of patients assigned to 
SIRT did not receive SIRT, a proportion consistent with 
our previously published data in patients with metastatic 
colorectal cancer.13 The difference in exposure to post-
trial treatments between the two treatment groups might 
have affected the primary endpoint. It is possible that the 
improved liver disease control observed in the FOLFOX 
plus SIRT group might have influenced physicians to 
bias towards less intensive subsequent treatment, 
particularly as so-called treatment-holiday strategies were 
evolving during the recruitment and follow-up periods of 
these trials. Alternatively, it could be postulated that the 
reduced use of irinotecan after protocol therapy might 
have been related to increased or prolonged toxicities in 
the patients in the FOLFOX plus SIRT group, including 
the risk of myelosuppression. Our analysis of these 
toxicities for both groups over time showed an apparent 
increase of grade 3 or worse adverse events in the 
FOLFOX plus SIRT group, particularly haematological 
events, with the curves gradually converging after 
6 months of protocol therapy.
In the past decade, the focus of clinical trials has been 
on improving outcomes for selected biological subtypes 
in metastatic colorectal cancer with predefined molecular 
criteria (eg, mutant RAS or BRAF). Several studies from 
the past 2 years have reported that patients with right-
sided primary tumours have worse survival outcomes 
and it is possible that these patients benefit less from 
standard therapies.28–30 Molecular subtypes in our study 
are not currently available, but in the dataset available, 
179 (25%) of 718 patients had right sided-tumours. Based 
on preliminary data currently available, patients with 
colorectal liver metastases from right-sided primary 
tumours could be a clinical subgroup that benefits from 
SIRT. Further analyses are underway to investigate this 
exploratory finding, with specific scrutiny of RAS 
mutation, BRAF mutation, and tumour location in study 
populations who have received SIRT in clinical trials. 
Further studies designed to define the potential benefit 
of SIRT to treat colorectal liver metastases from right-
sided primaries are warranted.
In conclusion, despite better liver-specific disease 
control and improved radiological response, the 
FOXFIRE prospective trials did not show a benefit of the 
combination of SIRT with FOLFOX for progression-free 
survival or overall survival. The routine early integration 
of SIRT in combination with oxaliplatin-based, first-line 
chemotherapy cannot be recommended as therapy for 
metastatic colorectal cancer. Further studies are needed 
to study the role of SIRT in carefully selected patient 
populations and as a consolidation therapy after 
chemotherapy.
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